37 participants
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-09-19
- Start Date:
- 2022-08-31
- Completion:
- 2022-12-22
Conditions
- Melanoma
- BRAF V600 Mutation
- Unresectable Melanoma
- Metastatic Melanoma
Interventions
- DRUG